• Test Code:
    1460
  • Department:
  • Test Synonyms:
    Fanconi Anemia sequencing panelFanconi Anemia NGSFANCAFANCBFANCCFANCD1/BRCA2FANCD2FANCEFANCFFANCGFANCIFANCJ/BRIP1FANCLFANCMFANCN/PALB2FANCO/RAD51CFANCP/SLX4BLMRAD51
  • CPT Code(s):
    81479x17
Background:

Fanconi Anemia (FA) is characterized by bone marrow failure, increased risk for cancer, and physical abnormalities.  Progressive bone marrow failure is responsible for the most significant morbidity and mortality.  Clinically heterogeneous, FA individuals are at increased risk for acute myelogenous leukemia, myelodysplasia, and solid tumors of the neck, head, oral cavities, and gynecological system.  Congenital abnormalities are present in FA patients and include: café au lait spots or hypopigmentation; short stature; radial ray defects; eye defects such as microphthalmia; malformations of the kidney, genitalia, heart, gastrointestinal tract, ears, and feet.  Currently, 15 genes corresponding to the known FA complementation groups, have been identified that, when mutated, can cause FA. Complementation testing is the current method to identify which gene is mutated in affected FA patients, followed by Sanger sequencing of the identified gene. Comprehensive next-generation sequencing techniques will eliminate the need for time intensive complementation analysis and identify the mutated FA gene with one test. Breakage analysis is still necessary to confirm the FA diagnosis.

Reasons for Referral:

  • Confirmation of clinical diagnosis in patients with classical or atypical Fanconi Anemia.
  • Sequence analysis of Fanconi Anemia associated genes following breakage analysis.

Methodology:

Component 1: Next generation sequencing will analyze the exons or coding regions of 15 Fanconi anemia-associated genes, as well as 2 additional genes which may be associated with the FA phenotype, using Illumina NextSeq 500 technology.  Samples are prepared using hybridization probes to enrich exonic regions.  Promoter, intronic, etc. regions are not assessed on our assay, but may contain variants that impact gene function.

Component 2:  A customized CytoSure “exon-centric” array (Oxford Gene Technology) will be used to detect deletions and duplications.  The targeted array has enhanced probes targeted to the exonic regions of 15 Fanconi anemia-associated genes, as well as 2 additional genes which may be associated with the FA phenotype.  The arrays are run using Agilent SureScan technology.

The 17 Fanconi anemia-associated genes are listed below:
FANCA, FANCB, FANCC, FANCD1 (BRCA2), FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ (BRIP1), FANCL, FANCM, FANCM, FANCN (PALB2), FANCO (RAD51C), FANCP (SLX4), BLM, RAD51

Specimen Requirements:

  • Blood:  EDTA or ACD (Solution A or B):
    • Adult: 5 mL
    • Child: 5 mL
    • Infant: 2-3 mL

A REQUISITION FORM MUST ACCOMPANY ALL SAMPLES.  Please include detailed clinical information, including ethnicity, clinical history, and family history.

Test Performed (Days):

Weekly

Turn Around Time:

Eight Weeks

Shipment Sensitivity Requirements:

  • Package and ship specimen to remain cold, but not frozen. 
  • Ship via overnight express, using the FedEx priority overnight label provided. 
  • Contact Client Services for shipping kits and instructions at (855) 535-1522.

References:

  1. Shimamura A, Alter B. Pathophysiology and management of inherited bone marrow failure syndromes Blood Reviews. 2010:101-122.
  2. Soulier J. Fanconi Anemia. American Society of Hematology Education Book. 2011(1):492-497.

Additional Info:

The Knight Cancer Institute at Oregon Health & Science University is a pioneer in the field of precision cancer medicine. The institute's director, Brian Druker, M.D., helped prove it was possible to shut down just the cells that enable cancer to grow. This breakthrough has made once-fatal forms of the disease manageable and transformed how cancer is treated. The OHSU Knight Cancer Institute is the only National Cancer Institute-designated Cancer Center between Sacramento and Seattle – an honor earned only by the nation's top cancer centers. It is headquarters for one of the National Cancer Institute's largest research collaboratives, SWOG, in addition to offering the latest treatments and technologies as well as hundreds of research studies and clinical trials.

Learn More